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Prevalence of morbidity associated with abortion before
and after legalisation in South Africa
Rachel Jewkes, Heather Brown, Kim Dickson›Tetteh, Jonathan Levin, Helen Rees
Abortion on request has been legal in South Africa
since 1997. The Choice in Termination of Pregnancy
Act of South Africa 1996 allows abortion on request
up to 20 weeks’ gestation. Since it was introduced,
40 000 legal abortions have been performed annually.1
A national study in 1994 on morbidity associated with
incomplete abortion (illegally induced and spontane›
ous miscarriage) assisted the act’s passage through
parliament.2
We studied the impact of legislative change on
morbidity and medical management by repeating the
1994 study of morbidity due to incomplete abortion
among patients presenting to public hospitals in 2000.3
Participants, methods, and results
Over different three week periods between May and
August, we collected data on all women presenting to
selected public hospitals with incomplete abortions
under 22 weeks’ gestation. We excluded legally induced
and threatened abortions. The sampling frame
included all public hospitals in the nine provinces of
South Africa responsible for treating women with
gynaecological problems in 2000. The sample was
stratified randomly by province and category of hospi›
tal (district, regional, and tertiary). In each stratum, two
hospitals were selected with the sampling probability
proportional to size (number of beds). Our sample
consisted of 47 hospitals, as five of the provinces had
one or no hospital in the tertiary stratum. A data cap›
ture sheet for each woman was completed from the
hospital records by healthcare staff.
We used three clinical severity categories for data
analysis and interpretation.4 Calculations were based
on population estimates for 1999 of 13 478 000
women aged 12›49 years and 1 106 000 live births,
where appropriate. The analysis took into account the
complex sample design, which was a stratified
multistage sample and was not self weighting. We used
the Rao Scott F test (part of the Stata package) to com›
pare the categorical variables with the 1994 study.2 5
The methods of the two studies differed in the sam›
pling of the hospitals. In 1994 the sample was stratified
only by the number of beds: all hospitals with over 499
beds and a random sample of hospitals with under 500
beds were sampled.
All 47 sampled hospitals responded, returning a
total of 761 data capture sheets. In 1994, 803 data cap›
ture sheets were returned. Three hospitals had no cases
of abortion during the study period. The incidence of
incomplete abortion per 100 000 women aged 12›49
years was 362 (range 282›441) compared with 375
(299›451) in 1994 (difference 13 (95% confidence
interval − 123 to 97) per 100 000). The rate of incom›
plete abortion per 100 000 live births was 44 (34›54)
compared with 42 (33›50) in 1994 (difference 2 ( − 11
to 15) per 100 ). There was one death in the 2000 study
period compared with three in the 1994 study.
The table shows the characteristics of the women,
clinical findings on admission, and changes in hospital
management. In 2000, only 7.8% of transfusions were
given to women with haemoglobin concentrations of
over 86 g/l. Antibiotics were not given to 55.5% and
Characteristics of women, clinical findings on admission relating
to abortion, and changes in hospital management, South Africa,
1994 (n=308) and 2000 (n=761). Values are percentages.
1994 2000
Test
statistic
P
value
Mean age; SD (years) 27.8; 7.2 27.0; 7.6 t=1.23 0.2
Median parity; range 1; 0›8 1; 0›11 — —
Trimester status:
12 weeks and under 60.5 67.1 F1,72=0.87 0.4
Over 12 weeks 39.5 32.9 — —
Signs of infection on admission (list is not exclusive):
None 79.5 90.1 F1,72=7.30 0.009
Offensive discharge 13.5 6.4 F1,72=6.71 0.01
Tender uterus 8.4 3.7 F1,72=3.05 0.09
Localised peritonitis 1.7 0.7 F1,72=1.43 0.2
Generalised peritonitis 0.1 0.1 F1,72=0.03 0.9
Septicaemic shock 0.3 0.2 F1,72=0.18 0.7
Signs of organ failure on admission:
None 95.6 97.1 F1,72=0.49 0.5
Disseminated intravascular
coagulation
0.4 0.2 F1,72=0.45 0.5
Respiratory distress 0.1 0.2 F1,72=0.36 0.6
Hypovolaemic shock 1.6 2.5 F1,72=0.39 0.5
Renal failure 1.8 0.1 F1,72=0.05 0.8
Other — 0.2 — —
Findings on evacuation:
Offensive products 12.6 9.4 F1,72=1.15 0.3
Mechanical or chemical injury
to genitals
3.2 0.6 F1,72=9.67 0.003
Foreign body 1.3 0 F1,72=4.36 0.04
Evidence of misoprostol
tablets
— 0.4 — —
Severity categories:
Low (no signs of infection) 66.2 72.4 F1.98,142.23=2.15 0.1
Medium (temperature
37.3›37.9°C and/or tender
uterus, offensive discharge, or
localised peritonitis on
admission)
17.3 17.9 — —
High (temperature over 37.9°C,
pulse rate over 119 beats/min,
any sign of interference, organ
failure, peritonitis, or death)
16.5 9.7 — —
Antibiotics given 43.6 33.5 F1,72=1.51 0.2
Blood or blood products given 13.4 8.3 F1,72=2.28 0.1
Evacuation: 88.9 87.8 F1,72=0.05 0.8
Sharp curettage 97.5 82.0 F2.22,157.27=4.59 0.01
Suction — 2.5 — —
Manual vacuum aspiration 1.5 14.8 — —
Other or not specified 1.0 0.7 — —
Analgesia or anaesthesia given:
None 4.5 7.8 F2.16,153.33=1.06 0.4
Local 1.1 3.9 — —
General 70.1 54.2 — —
Sedation 23.7 33.8 — —
Other 0.6 0.2 — —
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52.0% of women in the medium and high severity cat›
egories, respectively.
Comments
Legalisation of abortion in South Africa immediately
decreased morbidity but the magnitude was not
substantial, possibly because morbidity was already
lower than in many countries. The lack of change may
reflect additional covert induced abortion activity,
perhaps through the use of misoprostol in unregistered
settings. There has been a trend towards lower technol›
ogy. While more manual vacuum aspiration and less
general anaesthetic and blood transfusion is commend›
able, antibiotic use and pain relief seem inadequate. The
trend towards lower technology partially reflects success
of training programmes for induced abortion; however,
our findings suggest that further structured training in
the use of manual vacuum aspiration with paracervical
block and appropriate use of antibiotics and misopros›
tol would be beneficial.
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Drug points
Metabolic decompensation in pump users due to
lispro insulin precipitation
Howard A Wolpert, Raquel N Faradji, Susan Bonner›Weir, Myra A
Lipes, Joslin Diabetes Center, Boston, MA 02215, USA
Small, short term studies show that lispro insulin (Huma›
log; Eli Lilly & Co, Indianapolis, IN), commonly used in
pump therapy, is stable in insulin pumps.1 However, in
agreement with reports by others,2 we have noted several
patients who have developed erratic and unpredictable
glucose fluctuations with lispro insulin that have resolved
when the treatment was changed to buffered regular insu›
lin (Velosulin; Novo Nordisk, Princeton, NJ) and aspart
insulin (Novolog; Novo Nordisk, Princeton, NJ). We have
confirmed insulin precipitation in the infusion catheters
used by two patients.
Case 1
A 42 year old woman who had type 1 diabetes mellitus for
31 years had excellent glycaemic control (haemoglobin
A1c 6.1%) using buffered regular insulin in her Minimed
507C pump (Medtronic Minimed, Northridge, CA). Forty
hours after changing to lispro insulin she awoke from
sleep with nausea; her fingerstick blood glucose
concentration was 21.4 mmol/l and ketone bodies were
present in her urine. Troubleshooting revealed that her
Silouette infusion catheter was blocked (figure). Radioim›
munoassay confirmed that the precipitate occluding the
catheter was insulin. Her treatment was changed back to
buffered regular insulin and no recurrences of catheter
occlusion occurred. She subsequently changed to aspart
insulin and, to date, after five months has had no catheter
blockages.
Case 2
A 31 year old woman who had type 1 diabetes mellitus for
12 years (haemoglobin A1c 6.5%) was using a Disetronic
H›Tron V›100 pump (Disetronic Medical Systems, Minne›
apolis, MN). After her treatment was changed from
buffered regular insulin to lispro insulin, her glucose con›
centration sometimes fluctuated unexpectedly. These epi›
sodes resolved when the infusion catheter was removed.
The outer wall of the Sof›Set catheter that had been
removed after one of these episodes showed a white
precipitate, and staining with dithizone (diphenylthiocar›
bozone) confirmed that the precipitate was insulin (figure).
Patients who use lispro insulin in their pumps and
who have unpredictable glucose fluctuations should be
advised to consider changing to buffered regular insulin
or aspart insulin. The two cases described above indicate
that instability of lispro insulin is not specific to a particu›
lar infusion catheter or type of pump.
We thank Mr Richard Parent for helping to prepare the staining
of the catheters.
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Lispro insulin precipitate in infusion catheters for Case 1 (left) and Case 2 (right). Case 2
shows insulin precipitate stained with dithizone (diphenylthiocarbozone)
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